Effects of an angiotensin-converting enzyme inhibitor and a β-blocker on cerebral arterioles in rats

被引:51
|
作者
Chillon, JM
Baumbach, GL
机构
[1] Univ Iowa, Coll Med, Dept Pathol, Med Labs 100, Iowa City, IA 52242 USA
[2] Univ Iowa, Ctr Cardiovasc, Iowa City, IA 52242 USA
关键词
hypertension; chronic; vascular remodeling; angiotensin; hypertrophy; vascular;
D O I
10.1161/01.HYP.33.3.856
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We examined the effects of an angiotensin-converting enzyme inhibitor, perindopril, and a beta-blocker, propranolol, on cerebral arterioles in stroke-prone spontaneously hypertensive rats (SHRSP). The structure and mechanics of cerebral arterioles were examined in untreated Wistar-Kyoto rats (WKY) and SHRSP that were untreated or treated for 3 months with a high (2 mg/kg per day) or a low (0.3 mg/kg per day) dose of perindopril or propranolol (250 mg/kg per day) alone or in combination with the low dose of perindopril. We measured pressure, external diameter, and cross-sectional area of the vessel wall (CSA) in maximally dilated (with EDTA) cerebral arterioles. Treatment of SHRSP with the high dose of perindopril or the combination of propranolol and the low dose of perindopril normalized cerebral arteriolar mean pressure (50+/-1 [mean+/-SEM] and 43+/-2 mm Hg vs 50+/-1 mm Hg in WKY and 94+/-3 mm Hg in untreated SHRSP; P<0.05), pulse pressure (15+/-1 and 16+/-1 mm Hg vs 13+/-1 mm Hg in WKY and 35+/-1 mm Hg in untreated SHRSP; P<0.05), and CSA (1103+/-53 and 1099+/-51 mu m(2), respectively, vs 1057+/-49 mu m(2) in WKY and 1281+/-67 mu m(2) in untreated SHRSP; P<0.05). In contrast, treatment of SHRSP with the law dose of perindopril or propranolol alone did not normalize arteriolar pulse pressure (24+/-1 and 21+/-1 mm Hg) and failed to prevent increases in CSA (1282+/-77 and 1267+/-93 mu m(2)). Treatment with either dose of perindopril or the combination of propranolol and perindopril significantly increased external diameter in cerebral arterioles of SHRSP (99+/-3, 103+/-2, and 98+/-3 mu m vs 87+/-2 mu m in untreated SHRSP; P<0.05), whereas propranolol alone did not (91+/-3 mu m; P>0.05). These findings suggest that effects of angiotensin-converting enzyme inhibitors on cerebral arteriolar hypertrophy in SHRSP map depend primarily on their effects on arterial pressure, particularly pulse pressure, whereas their effects on cerebral arteriolar remodeling (defined as a reduction in external diameter) may be pressure independent.
引用
收藏
页码:856 / 861
页数:6
相关论文
共 50 条
  • [41] Role of angiotensin-converting enzyme inhibitor, lisinopril, on spermatozoal functions in rats
    Saha, L
    Garg, SK
    Bhargava, VK
    Mazumdar, S
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2000, 22 (03): : 159 - 162
  • [42] Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats
    Shimizu, Hideo
    Nakagami, Hironori
    Osako, Mariana Kiomy
    Nakagami, Futoshi
    Kunugiza, Yasuo
    Tomita, Tetsuya
    Yoshikawa, Hideki
    Rakugi, Hiromi
    Ogihara, Toshio
    Morishita, Ryuichi
    HYPERTENSION RESEARCH, 2009, 32 (09) : 786 - 790
  • [43] Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
    Boenner, G.
    Bakris, G. L.
    Sica, D.
    Weber, M. A.
    White, W. B.
    Perez, A.
    Cao, C.
    Handley, A.
    Kupfer, S.
    JOURNAL OF HUMAN HYPERTENSION, 2013, 27 (08) : 479 - 486
  • [44] Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention
    Ann, Soe Hee
    Strauss, Martin H.
    Park, Gyung-Min
    Han, Seungbong
    Yang, Yujin
    Kim, Yong-Giun
    Won, Ki-Bum
    Kim, Shin-Jae
    Lee, Sang-Gon
    Cho, Young-Rak
    Kim, Dae-Won
    Park, Mahn-Won
    Her, Sung Ho
    Lee, Seung-Whan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 306 : 35 - 41
  • [45] Angiotensin-Converting Enzyme Inhibitor, Angiotensin Receptor Blocker Use, and Mortality in Patients With Chronic Kidney Disease
    Molnar, Miklos Z.
    Kalantar-Zadeh, Kamyar
    Lott, Evan H.
    Lu, Jun Ling
    Malakauskas, Sandra M.
    Ma, Jennie Z.
    Quarles, Darryl L.
    Kovesdy, Csaba P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (07) : 650 - 658
  • [46] Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor
    Sleight, Peter
    JOURNAL OF HYPERTENSION, 2009, 27 : S23 - S29
  • [47] THE ANTIPROTEINURIC EFFECT OF COMBINED ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND ANGIOTENSIN RECEPTOR BLOCKER THERAPY IN PRIMARY GLOMERULONEPHRITIS
    Kaptanogullari, Ozlem Harmankaya
    Ozbahar, Yalcin
    Cecen, Ismail
    Kaptanogullari, Hakan
    NEPHROLOGY, 2005, 10 : A168 - A168
  • [48] Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient
    Jarred, Ghassan
    Kennedy, R. Lee
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2010, 1 (01) : 23 - 28
  • [49] Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use Among Hypertensive US Adults With Albuminuria
    Chu, Chi D.
    Powe, Neil R.
    McCulloch, Charles E.
    Banerjee, Tanushree
    Crews, Deidra C.
    Saran, Rajiv
    Bragg-Gresham, Jennifer
    Morgenstern, Hal
    Pavkov, Meda E.
    Saydah, Sharon H.
    Tuot, Delphine S.
    HYPERTENSION, 2021, 77 (01) : 94 - 102
  • [50] Clinical Value of Angiotensin-converting Enzyme Inhibitor and Angiotensin Receptor Blocker in the Patients of Coronary Artery Disease
    Abe, Daisuke
    Sato, Akira
    Misaki, Masako
    Takeyasu, Noriyuki
    Hoshi, Tomoya
    Aonuma, Kazutaka
    CIRCULATION, 2013, 128 (22)